Liquidia, GlaxoSmithKline deal

Liquidia granted GlaxoSmithKline exclusive, worldwide rights to develop certain vaccines and inhaled products using Liquidia's Particle Replication In Non-Wetting Templates (PRINT) drug delivery techn...